webinar register page

Webinar banner
BioTech - Cancer
Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to treatment, particularly in solid tumors?

Oct 25, 2022 12:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information


Abderrahmane Laadem, MD,
Vice President, Global Head of Translational Development @AstraZeneca and Daiichi Sankyo Co.
Abderrahmane Laadem, MD, is a medical oncologist with more than 25 years of clinical research experience in oncology, hematology and rare diseases. Currently, Dr. Laadem is the Interim Head of Global Oncology Development and Vice President of Early Clinical Development at Daiichi Sankyo, where he oversees the global development of all oncology medicines including the company’s DXd antibody drug conjugate (ADC) and hematology portfolio. Prior to joining Daiichi Sankyo in 2020, Dr. Laadem held roles of increasing responsibility for 10 years at Celgene (now Bristol Myers Squibb), including serving as Vice President of Worldwide Medical for all myeloid assets and the Global Team Lead for luspaterecept, a treatment for beta thalassemia and myelodysplastic syndromes. Additionally, during his time at Celgene, Dr. Laadem built one of the largest and most agile scientific teams comprised of MDs and PhDs in the hematology/oncology space.
Lusong Luo
Senior VP, External Innovation @BeiGene
Dr. Lusong Luo is the SVP & Head of External Innovation at BeiGene. Prior to taking this role, Dr. Luo is SVP & Head of Discovery Biology at BeiGene. Dr. Luo is one of the founding scientists of BeiGene. In addition to his current role at BeiGene, Dr. Luo serves as the acting CEO, president and Board member of MapKure, LLC. Dr. Luo also serves as a board member for BITT (Boston Immune Technologies & Therapeutics). Before joining BeiGene, Dr. Luo held positions in BioDuro as Sr. Director and Director of Discovery Biology. Dr. Luo has also spent a number of years at GlaxoSmithkline Oncology CEDD, where he served as Group Manager, Research Investigator, and Principal Scientist. Dr. Luo was a key member of a number of oncology drug discovery/development teams that have contributed to the discovery & development of over dozen clinical compounds over the years, among them five have obtained regulatory approval. Dr. Luo has published more than 60 research papers, reviews, and book chapters.
Kristen Hege
Senior Vice President, Early Clinical Development, Oncology/Hematology and Cell Therapy @Bristol Myers Squibb
Kristen Hege is a physician who has been board-certified in hematology, medical oncology and internal medicine. Following the acquisition of Celgene in 2019, Kristen joined Bristol Myers Squibb (BMS) as the SVP of Early Clinical Development, Hematology/Oncology & Cell Therapy. Based in San Francisco, Kristen focuses on developing innovative cancer treatments to combat hard-to-treat diseases and is responsible for overseeing early clinical development programs for a diverse range of treatment modalities such as CAR T cells, T-cell engagers, monoclonal antibodies and small molecules. She and her team of physicians and clinical scientists use translational insights to shape clinical trials, guide biomarker strategies and inform asset development. In addition to her work at BMS, Kristen continues to work part-time as a clinical professor of medicine at the University of California-San Francisco where she sees patients with blood cancers weekly.
Robert Iannone, MD, MSCE,
Executive Vice President, Global Head of Research and Development @Jazz Pharmaceuticals
Robert Iannone has been Jazz’s executive vice president and global head of research and development since May 2019. Dr. Iannone oversees all aspects of preclinical research and clinical development, clinical operations and regulatory affairs. He brings more than 16 years of experience in clinical drug development, having worked across therapeutic areas and phases of development, most recently on immuno-oncology programs at Merck, AstraZeneca and Immunomedics. From April 2018 until May 2019, Dr. Iannone served as head of research and development and chief medical officer of Immunomedics, Inc. Prior to that, from July 2014 to April 2018, Dr. Iannone served in the roles of senior vice president and head of immuno-oncology, global medicines development and the global products vice president at AstraZeneca plc. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc. since January 2020 and in 2021, was appointed to the board of directors for iTeos Therapeutics.
Michael Ringel, PhD (Moderator)
Managing Director and Senior Partner, Global Leader, Growth & Innovation Analytics @BCG Boston Consulting Group
Michael Ringel is a Managing Director and Senior Partner at BCG, and BCG’s Global Topic Leader for Growth and Innovation. He is a frequent author and speaker on R&D and innovation topics. His TED talk on innovation can be viewed at TED.com. He is also Strategic Advisor to Life Biosciences, a company targeting aging biology to address multiple diseases. Prior to BCG, Michael worked in academia, pursuing research in theoretical population dynamics and conducting field experiments in the Amazon basin near Manaus, Brazil. Michael holds a B.A. summa cum laude in biology from Princeton, a Ph.D. in biology from Imperial College, and a J.D. cum laude from Harvard Law School.